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BACKGROUND & AIMS: The intestinal immune sys-
tem is tightly regulated to prevent responses against the
many nonpathogenic antigens in the gut. Transforming
growth factor (TGF)- is a cytokine that maintains intes-
inal homeostasis, in part by inducing Foxp3 regulatory
cells (Tregs) that suppress immune responses. TGF- is
expressed at high levels in the gastrointestinal tract as a
latent complex that must be activated. However, the path-
ways that control TGF- activation in the intestine are
poorly defined. We investigated the cellular and molecular
pathways that control activation of TGF- and induction
f Foxp3 Tregs in the intestines of mice to maintain
immune homeostasis. METHODS: Subsets of intestinal
dendritic cells (DCs) were examined for their capacity to
activate TGF- and induce Foxp3 Tregs in vitro. Mice
were fed oral antigen, and induction of Foxp3 Tregs was
measured. RESULTS: A tolerogenic subset of intestinal
DCs that express CD103 were specialized to activate la-
tent TGF-, and induced Foxp3 Tregs independently of
he vitamin A metabolite retinoic acid. The integrin v8,
which activates TGF-, was significantly up-regulated on
D103 intestinal DCs. DCs that lack expression of in-
tegrin v8 had reduced ability to activate latent TGF-
and induce Foxp3 Tregs in vitro and in vivo. CONCLU-
SIONS: CD103 intestinal DCs promote a tolerogenic
nvironment in the intestines of mice via integrin
v8-mediated activation of TGF-.
Keywords: Immune Response; T-Cell Regulation; Signal-
ing; Inflammatory Response; Self Tolerance.
The intestinal immune system encounters a wealth ofantigenic stimulation consisting of food substances
nd commensal bacteria that inhabit the gut.1 Regulatory
processes must therefore prevent detrimental immune
responses to these harmless antigens while still being able
to mount protective responses against pathogens that
enter the digestive tract. A breakdown in this tight regu-
lation can lead to debilitating autoimmunity and inflam-
matory bowel disease.
Strong evidence exists that CD4 regulatory T cells
(Tregs) play a crucial role in regulating inflammatory
responses at environmental interfaces such as the gut.2The most prevalent subset of Tregs, marked by expressionof the transcription factor Foxp3, can arise naturally in
the thymus during T-cell development (natural Tregs) or
can be induced in the periphery from naïve CD4 T cells
(inducible Tregs [iTregs]).3 Induction of iTregs is depen-
ent on T-cell receptor stimulation and the cytokine
ransforming growth factor (TGF)-4 and has been pro-
posed to be important in maintaining gut immune toler-
ance.2 However, the mechanisms underlying iTreg induc-
ion in the gut are poorly understood.
Given their fundamental importance in regulation of
-cell responses, dendritic cells (DCs) have been suggested
o play a central role in regulating Foxp3 Treg responses
nd tolerance in the intestine.5 Acting as the sentinels of
he gut, these cells are decisively positioned throughout
he intestine to capture luminal contents and process and
resent these antigens to T cells within the gut-draining
esenteric lymph node (mLN). Several lines of investiga-
ion have indicated that DCs marked by the expression of
D103 have important tolerogenic properties, with re-
uced production of proinflammatory cytokines and an
nhanced ability to induce Foxp3 iTregs.6,7 The ability of
CD103 intestinal DCs to induce iTregs has been linked
o their ability to produce enhanced levels of the dietary
etabolite retinoic acid (RA) via enhanced expression of
etinal dehydrogenase aldh1a2.6,7 Such RA-mediated iTreg
induction by CD103 intestinal DCs requires synergy
with the key immunoregulatory cytokine TGF-. TGF- is
ighly expressed in the intestine but importantly is always
roduced as a latent protein complex that must be acti-
ated to exert biologic function.8 However, the cellular
and molecular mechanisms that regulate TGF- activity
nd iTreg induction in the intestine are not known.
In this study, we show that intestinal CD103 DCs are
pecialized to generate Foxp3 iTregs independent of the
actions of RA. We found that CD103 DCs from the
intestine have an increased ability to activate latent TGF-
that is directly responsible for their increased ability to
induce iTregs. Furthermore, we find that intestinal
CD103 DCs express greatly elevated levels of the TGF-
Abbreviations used in this paper: DC, dendritic cell; LAP, latency-
associated peptide; mIgG, mouse immunoglobulin G; mLN, mesenteric
lymph node; qPCR, quantitative polymerase chain reaction; RA, retinoic
acid; TGF, transforming growth factor; Treg, regulatory T cell; iTreg,
inducible regulatory T cell.
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November 2011 TGF- ACTIVATION BY TOLEROGENIC GUT DENDRITIC CELLS 1803–activating integrin v8, which is absolutely required
or both their enhanced ability to activate latent TGF-
and their specialized ability to induce iTregs in vitro and
in vivo. These results highlight a novel mechanism by
which CD103DCs in the intestine promote Foxp3 Treg
nduction and bring to the forefront integrin-mediated
GF- activation in promoting tolerance within the gut.
Materials and Methods
Animals
Mice lacking integrin v8 on DCs via expression of a
onditional floxed allele of 8 integrin in combination with
CD11c-Cre (Itgb8 (CD11c-Cre) mice) have been previously de-
scribed.9 OT-II/Rag/ and Foxp3GFP mice10 were kind gifts
from Dr K Okkenhaug (Babraham Institute, Cambridge, Eng-
land) and Dr A. Rudensky (Memorial Sloan-Kettering Cancer
Center, New York, NY), respectively. All mice were maintained in
specific pathogen-free conditions at the University of Man-
chester and used at 6 to 8 weeks of age. All experiments were
performed under the regulations of the Home Office Scientific
Procedures Act (1986).
Purification of DCs
Mouse mLN or spleen was incubated with shaking for
20 minutes at 37°C in RPMI-1640 with 0.08 U/mL Liberase
Blendzyme 3 (Roche, Burgess Hill, United Kingdom) or 1
mg/mL collagenase VIII and 50 U/mL deoxyribonuclease I, re-
spectively. Small/large intestinal lamina propria were excised
and prepared as described.11 Cells were blocked with anti-FcR
antibody (clone 24G2) before enrichment using a CD11c enrich-
ment kit (Miltenyi Biotec, Bisley, United Kingdom). To purify
CD103/ DCs, enriched DCs were labeled with anti-CD103
M290) and anti-CD11c (N418) antibodies and sorted using a
ACSAria (BD Biosciences, San Jose, CA). In all experiments,
ubset purity was 95%.
T-Cell Purification
Splenocytes from Foxp3GFP mice were stained with anti-
D4 (GK1.5) and anti-CD44 (IM7) antibodies and CD4
CD44/low, GFP populations sorted using a FACSAria. Cell
purity in all experiments was 99.8%.
In Vitro Treg Induction Assay
A total of 5  104 CD4 CD44/low, Foxp3GFP T cells
isolated from Foxp3GFP mice were cultured with 2.5  103
CD103/ DC subsets in RPMI 1640 media (10% FBS, 1%
penicillin/streptomycin, 1% L-glutamine, 50 m 2-mercapto-
thanol) with 0.06 g/mL -CD3 antibody for 5 days with
ddition of 5 ng/mL recombinant human interleukin-2 every
ther day. Induction of CD4 Foxp3GFP Tregs was analyzed by
ow cytometry, with cells stained with anti-CD4 and 47
(DATK-32) antibodies. Cell viability was assessed using 7-AAD.
In addition, 40 g/mL control mouse immunoglobulin G
mIgG) or –TGF- antibody (clone 1D11), 2 ng/mL recombi-
ant human TGF-, 100 nmol/L all-trans RA, and/or 1 mol/L
A receptor inhibitors LE540 and LE135 were added as indi-
ated.
In Vivo Treg Assay
CD4 T cells from OTII/Rag/ mouse spleens werenriched using a CD4 enrichment kit and AutoMACS (Miltenyiiotec), stained with anti-CD4 and V2 (B20.1) antibodies, and
sorted for CD4, V2 cells on a FACSAria. Purity obtained was
99.8% in all experiments. Cells were labeled with 2 mol/L
carboxyfluorescein succinimidyl ester, 2  106 cells injected
ntravenously into control or Itgb8 (CD11c-Cre) recipient mice,
nd mice fed ovalbumin (10 mg/mL) in drinking water for 5
ays. On day 6, spleen/lymph node cells were harvested and
tained with anti-CD4, V2, and Foxp3 (FJK-16s) antibodies.
nduced carboxyfluorescein succinimidyl ester–labeled Foxp3
cells were detected by flow cytometry.
TGF- Activation Assay
CD103/ DCs were incubated with mink lung epithe-
lial cells transfected with a plasmid containing firefly luciferase
complementary DNA downstream of a TGF-–sensitive pro-
moter12 in the presence of 1 g/mL lipopolysaccharide. Cocul-
tures were incubated overnight in the presence of 40 g/mL
ontrol mIgG or anti–TGF- antibody (clone 1d11) and lu-
ciferase detected via the Luciferase Assay System (Promega,
Southampton, United Kingdom). TGF- activity was deter-
mined as the difference in luciferase activity between control
mIgG-treated samples and samples treated with anti–TGF-
antibody.
Quantitative Polymerase Chain Reaction
Total RNA was purified from sorted DC subsets using
an RNeasy Mini Kit (Qiagen, Crawley, United Kingdom). RNA
was reverse transcribed using oligo(dT) primers and complemen-
tary DNA for specific genes detected using a SYBR Green qPCR
Kit (Finnzymes, Vantaa, Finland). Gene expression was normal-
ized to HPRT levels (see Supplementary Table 1 for primers
used).
Statistical Analysis
Results are expressed as mean  SEM. Where statistics
are quoted, 2 experimental groups were compared using the
Student t test for nonparametric data. Three or more groups
were compared using the Kruskal–Wallis test, with Dunn’s mul-
tiple comparison posttest. P  .05 was considered statistically
significant.
Results
The Enhanced Ability of Intestinal CD103
DCs to Induce Foxp3 iTregs Is Due to an
Increased Ability to Activate TGF- and Does
Not Require RA
Recent data have indicated that a CD103 subset
of intestinal DCs promotes de novo generation of Foxp3
iTregs.6,7 However, the molecular mechanisms driving this
process are not clear. We first addressed whether en-
hanced induction of Foxp3 iTregs was a general property
of CD103 DCs or whether this property was distinct to
intestinal DCs. As previously shown,6,7 we found that
CD103DCs isolated from the gut-draining mLN have an
enhanced ability to induce Foxp3 iTregs compared with
D103 DCs (Figure 1A). However, CD103/ subsets
solated from spleen showed an equivalent capacity to
nduce Foxp3 iTregs, similar to levels seen with CD103
DCs from mLN (Figure 1A). Hence, enhanced Foxp3iTreg induction seems to be a specific property of intes-
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1804 WORTHINGTON ET AL GASTROENTEROLOGY Vol. 141, No. 5tinal CD103 DCs rather than a general property of
D103 DCs.
Because CD103 DCs from the intestine are specialized
to induce Foxp3 iTregs, we sought to identify novel
echanisms responsible for this property. Work has pro-
osed that the enhanced ability of CD103 intestinal DCs
Figure 1. RA is not essential for the enhanced ability of CD103 intest
ere incubated with 2.5 103 CD103/ DCs in the presence of anti-C
induction of iTregs (CD4 Foxp3GFP) was assessed by flow cytometry a
f exogenous TGF-. (B) CD103/ DCs from mLN in the presence of
E-450). (C) CD103/ DCs from mLN in the absence of exogenous a
antibody. (D) CD103/ DCs from mLN in the presence of 100 nmol/L R
3 independent experiments. *P .05, **P .01. (E) Representative flow
CD4 T-cell expression of Foxp3GFP and 47.to induce iTregs is due to the elevated production of the ovitamin A metabolite RA, resulting from elevated expres-
sion of the RA-metabolizing enzyme ALDH1a2.7 Indeed,
as previously reported,6,7 in the presence of exogenous
active TGF-, the enhanced ability of intestinal CD103
DCs to induce Foxp3 iTregs is prevented by the inhibi-
ion of RA (Figure 1B). Additionally, RA rescues the ability
DCs to induce Tregs. (A–E) A total of 5  104 CD4 Foxp3GFP T cells
antibody and/or RA, RA inhibitors, and/or anti–TGF- antibody, and the
r 5 days. (A) CD103/ DC subsets from mLN or spleen in the absence
g/mL TGF- and 100 nmol/L RA or 1 mol/L of RA inhibitors (LE-135,
e TGF- and/or 1 mol/L RA inhibitors and/or 40 g/mL anti–TGF-
d/or 40 g/mL anti–TGF- antibody. Data are representative of at least
tometry plots from C and D analyzing effects of RA inhibitors and RA oninal
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November 2011 TGF- ACTIVATION BY TOLEROGENIC GUT DENDRITIC CELLS 1805CD103 DCs (Figure 1B). However, because these and
revious experiments involve addition of high levels of
xogenous active TGF-, the relative contribution of TGF-
/RA to enhanced induction of iTregs by intestinal
CD103 DCs cannot be assessed. To address this point,
we repeated experiments in the absence of exogenous
active TGF-. Interestingly, when RA was inhibited in the
bsence of exogenous TGF-, CD103 intestinal DCs
ere still capable of inducing elevated levels of Foxp3
iTregs versus CD103 intestinal DCs (Figure 1C). Simi-
arly, addition of exogenous RA to cultures did not rescue
he ability of CD103 DCs to induce iTregs to levels seen
ith CD103DCs (Figure 1D). This was despite the fact that
he induction of RA-dependent gut-homing receptor 47
was blocked by RA inhibition and induced by addition of RA
(Figure 1E). Strikingly, however, antibody-mediated block-
de of TGF- function completely abrogated the enhanced
bility of intestinal CD103 DCs to induce Foxp3 Tregs
nder all conditions (Figure 1C and D). Collectively, these
ata show for the first time that intestinal CD103 DCs can
referentially induce Foxp3 iTregs independently of RA
nd this enhanced induction is totally dependent on TGF-.
e therefore sought to identify novel mechanisms respon-
ible for the specialization of intestinal CD103 DCs to
generate iTregs.
Because TGF- is produced as a latent complex that
ust be activated to function, we hypothesized that in-
estinal CD103 DCs either produce elevated levels of
latent TGF- or are specialized to activate TGF-. To test
these hypotheses, we directly measured the ability of in-
testinal CD103/ DCs to produce and activate latent
GF-. Using quantitative polymerase chain reaction
(qPCR), we found no significant increase in the ability of
CD103 intestinal DCs to produce latent TGF- messen-
er RNA versus CD103 intestinal DCs (Figure 2A). Im-
ortantly, however, using a bioassay to detect the acti-
ated form of TGF-,12 intestinal CD103 DCs showed a
greatly enhanced ability to activate latent TGF- when
compared with CD103 DCs (Figure 2B). These results
Figure 2. CD103 intestinal DCs have an increased ability to activate
atent TGF-. (A) Latent TGF- production by CD103/ mLN DCs was
ssessed by qPCR and levels normalized to the housekeeping gene
PRT. Data represent 3 independent experiments. (B) Production of
ctive TGF- by CD103/ DCs from mLN was assessed by culturing
DCs with an active TGF- reporter cell line.12 Data represent 3 indepen-
dent experiments. **P  .01.strongly suggest that elevated Foxp3 iTreg induction by
ntestinal CD103 DCs is driven by their enhanced ability
o activate latent TGF-.
Elevated Expression of the Integrin v8 by
Intestinal CD103 DCs Is Responsible for
Their Enhanced Ability to Activate TGF-
We next aimed to determine the mechanisms that
support enhanced latent TGF- activation by intestinal
CD103 DCs. Recent evidence has highlighted an impor-
tant role for specific integrin receptors in modulating
activation of TGF- via binding to an RGD integrin
binding motif present in the latency-associated peptide
(LAP) region of latent TGF-.13 When we analyzed total
D11c DCs, we saw a marked increase in expression of
the TGF-–activating integrin receptor v8 on DCs iso-
lated from mLN compared with spleen (Figure 3A). Strik-
ingly, we found a highly significant (50-fold) increase in
expression levels of integrin v8 on intestinal CD103
DCs compared with CD103 DCs (Figure 3B). Enhanced
xpression of integrin v8 appeared specific to intestinal
D103 DCs, because splenic CD103/ DC subsets
showed equivalent expression of integrin v8, similar to
levels seen in intestinal CD103 DCs (Figure 3B).
To test the functional role of increased integrin v8
xpression by intestinal CD103 DCs, we utilized DC
ubsets isolated from Itgb8 (CD11c-Cre) conditional KO
ice that specifically lack integrin v8 on CD11cDCs.9
We found that the enhanced ability of intestinal CD103
DCs to activate latent TGF- was completely ablated in
v8/ CD103 DCs (Figure 3C). Indeed, the level of
TGF- activation seen by v8/ intestinal CD103 DCs
was similar to that seen with wild-type CD103 DCs
(Figure 3C). Importantly, such reduced TGF- activation
as not due to a decreased ability to produce latent
GF-, because expression of latent TGF- by control and
v8-deficient DCs was similar (Figure 3D). Therefore,
enhanced expression of integrin v8 by intestinal
CD103 DCs is critical for the increased ability of these
ells to activate latent TGF-.
The Enhanced Ability of Intestinal CD103
DCs to Induce Foxp3 iTregs Is Wholly
Dependent on TGF- Activation by
Integrin v8
To assess if increased expression of the TGF-–
ctivating v8 integrin on intestinal CD103 DCs was
responsible for their enhanced ability to induce Foxp3
iTregs, we compared the ability of v8/ intestinal DC
subsets to induce iTregs ex vivo. In the absence of integrin
v8, the enhanced ability of intestinal CD103 DCs to
induce Foxp3 iTregs was completely ablated, similar to
levels seen for CD103 DCs (Figure 4A). Importantly, the
ddition of exogenous active TGF- completely rescued
iTreg induction by v8/ intestinal CD103 DCs to
levels seen with control CD103 DC subsets (Figure 4B).
ddition/inhibition of RA failed to rescue the ability of
v8/ intestinal CD103 DCs to induce iTregs (Sup-
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1806 WORTHINGTON ET AL GASTROENTEROLOGY Vol. 141, No. 5plementary Figure 1A and B). Indeed, the absence of v8
integrin did not affect the increased expression of aldh1a2
messenger RNA by intestinal CD103 DCs or their in-
creased ability to induce the gut homing receptor 47 on
responding CD4 T cells (Supplementary Figure 2A and
), showing that lack of integrin v8 does not affect the
nhanced ability of CD103 intestinal DCs to produce
RA. v8/ CD103 DCs also showed reduced produc-
tion of inflammatory cytokines compared with CD103
DCs6 (Supplementary Figure 3), indicating that reduced
TGF- activation by v8 does not result in an overt
proinflammatory phenotype in CD103 intestinal DCs.
Data presented previously were obtained using intesti-
al DC subsets isolated from mLN, which include DCs
raining from the small and large intestine. To determine
hether CD103 DCs present within intestinal tissues
show a similar reliance on integrin v8-mediated TGF-
activation to induce Foxp3 iTregs, we first analyzed ex-
ression of 8 integrin on DCs isolated from small and
arge intestinal lamina propria. Similar to mLN DC sub-
ets, CD103 DCs from both the small and large intestine
expressed high levels of 8 integrin (Figure 5A). Addition-
lly, CD103 DCs from both small and large intestine
Figure 3. CD103 intestinal DCs express elevated levels of the TGF
ependent manner. RNA from (A) total DCs or (B) splenic/mLN CD103
ormalized to the housekeeping gene HPRT and presented relative to le
re representative of 2 and 4 independent experiments, respectively. (C)
y coculture with an active TGF- reporter cell line.12 Data represent 5 in
as analyzed for TGF- expression by qPCR. Data shown represent 2supported enhanced Foxp3 iTreg induction versus CD103DCs, which was completely reliant on expression of integrin
v8 (Figure 5B). As observed for mLN, iTreg induction in
v8/ CD103 DCs from small or large intestine was
escued by addition of active TGF- (Figure 5C). Interest-
ngly, we observed slightly elevated expression of 8 on
CD103 DCs from large intestinal lamina propria versus
D103 DCs from small intestine (Figure 5A), mLN, and
spleen (data not shown). However, such expression did
not translate into an enhanced ability to induce iTreg,
indicating a potentially novel role for 8 expression on
D103 DCs from the large intestine (Figure 5B). Taken
together, these data show that increased v8-mediated
TGF- activation by intestinal CD103 DCs is critical for
heir enhanced ability to induce Foxp3 iTregs ex vivo.
The Absence of Integrin v8 on Intestinal
DCs Leads to an Absence of Foxp3 iTreg
Induction In Vivo During Oral
Administration of Antigen
We next sought to determine whether integrin
v8 expression by intestinal DCs supported enhanced
Foxp3 iTreg induction in vivo. To this end, we adoptively
ransferred ovalbumin antigen-specific CD4 OT-II T
ctivating integrin v8 and activate more TGF- in an integrin v8-
DCs was analyzed for integrin 8 expression by qPCR. 8 levels were
in total spleen DCs (for A) or spleen CD103-ve DCs (for B). Data shown
F- activation by control or v8/ CD103/ mLN DCs was detected
pendent experiments. (D) RNA from control or v8/ CD103/ DCs
pendent experiments. *P  .05, **P  .01.-a
/
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November 2011 TGF- ACTIVATION BY TOLEROGENIC GUT DENDRITIC CELLS 1807mented drinking water with ovalbumin. T cells were iso-
lated from OT-II/Rag/ mice, which lack endogenous
Foxp3 Tregs. Previous experiments using this method
ave shown that Foxp3 iTreg induction is promoted
specifically in the mLN, at least in part via the enhanced
ability of intestinal CD103 DCs to promote iTreg induc-
ion.6,7
In control mice, we observed 5% induction of Foxp3
iTregs arising from adoptively transferred OT-II T cells
specifically within the mLN (Figure 6A). This induced
population was not observed in the spleen or in mice not
fed ovalbumin (data not shown). Strikingly, induction of
Foxp3 iTregs in mLN was completely absent in mice
acking integrin v8 on DCs (Figure 6A), despite a sim-
lar number of transferred CD4 T cells being detected in
the mLN of Itgb8 (CD11c-Cre) and control mice (Figure
6B). Because TGF- can induce expression of CD103 in
ome cells,14 a potential explanation for the reduced abil-
ty of Itgb8 (CD11c-Cre) mice to induce iTregs is that lower
Figure 4. Integrin v8-mediated TGF- activation is critical for the en
 104 CD4 Foxp3GFP T cells were cultured with 2.5 103 control or
(A) 40 g/mL mIgG or anti–TGF- antibody or (B) 2 ng/mL exogenous a
5 days. Representative flow cytometry plots and data are shown from 3CD103 DC numbers are present in these mice owing toreduced TGF- activation. However, we found that Itgb8
(CD11c-Cre) mice had comparable numbers of CD103
DCs in all gut-associated lymphoid tissue examined (Fig-
ure 6C). Taken together with our in vitro data, these
results strongly indicate that v8-mediated TGF- acti-
vation by specialized intestinal CD103 DCs is essential
for the induction of tolerogenic Foxp3 iTregs in the gut.
Discussion
Intestinal CD103 DCs have emerged as key cells
n maintaining gut tolerance, with recent data showing
hat these cells have the enhanced ability to induce gut-
oming receptors on responding T cells15 and convert naïve
T cells to immune-suppressive Foxp3 iTregs.6,7 These im-
portant functions appear to be due to high expression of the
retinal dehydrogenase aldh1a2 in CD103 intestinal DCs,
suggesting they have the capacity to metabolize retinal
acid to RA.6 However, our data now show that CD103
ced ability of CD103 intestinal DCs to induce Foxp3 Tregs. A total of
8/ CD103/ DC subsets in the presence of anti-CD3 antibody plus
e TGF-. Foxp3 Treg induction was assessed by flow cytometry after
5 independent experiments, respectively. *P  .05, **P  .01.han
v
ctivgut DCs have an enhanced ability to induce iTregs that is
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1808 WORTHINGTON ET AL GASTROENTEROLOGY Vol. 141, No. 5Figure 5. Elevated expression of integrin v8 by small and large intestinal lamina propria CD103 DCs is required for enhanced induction of
oxp3 Tregs. (A) Integrin 8 expression in small/large intestinal lamina propria CD103/ DCs was assessed by qPCR, normalizing levels to the
housekeeping gene HPRT. Data are presented as relative to small intestinal CD103-ve DC levels and represent 3 independent experiments. (B and
C) A total of 5  104 CD4 Foxp3GFP T cells were cultured with 2.5  103 control or v8/ CD103/ DC subsets in the presence of anti-CD3
antibody plus (B) mIgG or anti–TGF- antibody or (C) exogenous active TGF-. Foxp3 Treg induction was assessed by flow cytometry after 5 days.
Representative flow cytometry plots and data are shown from 2 to 6 independent experiments. *P  .05, **P  .01.
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November 2011 TGF- ACTIVATION BY TOLEROGENIC GUT DENDRITIC CELLS 1809independent of RA but completely dependent on TGF-
function. These results strongly suggest that the en-
hanced ability of CD103 intestinal DCs to induce iTregs
s linked to an increased ability of these cells to produce
ctive TGF-. Indeed, we directly show for the first time
hat CD103 intestinal DCs are specialized to activate
atent TGF- and that elevated expression of the TGF-–
activating integrin v8 by CD103 intestinal DCs is
responsible for the enhanced ability of these cells to acti-
vate latent TGF-. Importantly, elevated integrin v8-
mediated TGF- activation by CD103 intestinal DCs is
esponsible for their increased ability to induce Foxp3
Tregs both in vitro and in vivo. We have therefore
identified a novel molecular pathway by which a spe-
cialized gut DC subset activates TGF- to promote a
tolerogenic environment via induction of Foxp3
iTregs.
Many different immune cells produce TGF- (predom-
nately the isoform TGF-116) but always noncovalently
ound to an N-terminal propeptide (LAP), preventing
GF- binding to its receptor.8 Hence, TGF- function is
xquisitely regulated at the level of TGF- activation.
Figure 6. Integrin v8-mediated TGF- activation is critical for the e
dministration of antigen. A total of 2  106 carboxyfluorescein succi
intravenously into control or Itgb8 (CD11c-Cre) mice. Recipient mice were
cells after 6 days. (A) Representative flow cytometry plots and pooled
transferred cells in mLN of recipient mice. (C) Proportion of CD103 DCs
arge intestine lamina propria (LILP) of control and Itgb8 (CD11c-Cre) mtrong evidence in vivo now supports a critical role forntegrin receptors in activating latent TGF-1 via interac-
tion with an RGD integrin binding motif present in the
LAP region of the latent complex.17 Our finding that the
TGF-–activating integrin v8 is highly expressed and
functionally important on specialized tolerogenic DCs in
the intestine correlates with our previous findings that
Itgb8 (CD11c-Cre) mice develop severe colitis associated
with reduced levels of total Foxp3 Tregs in the colonic
lamina propria.9 Indeed, this reduction is likely due to an
absence of iTregs as opposed to natural Tregs, because we
now show that Itgb8 (CD11c-Cre) mice fail to establish an
Treg population in the mLN upon antigen stimulation of
doptively transferred CD4 T cells. Our results therefore
ndicate that elevated expression of integrin v8 by
D103 intestinal DCs plays an important role in pre-
venting gut inflammation via induction of Foxp3 iTregs.
In addition to activation by integrins, several other
mechanisms of TGF- activation have been proposed,
ncluding cleavage by the protease plasmin, MMP2 and
MP9, and interaction with thrombospondin-1.8 How-
ever, mice lacking these molecules show mild/no inflam-
mation of the gut, indicating a minimal role in the acti-
nced ability of intestinal DCs to induce Foxp3 Tregs in vivo after oral
idyl ester–labeled CD4 T cells from OTII/Rag/ mice were injected
ovalbumin in drinking water and mLN analyzed for CD4 V2 Foxp3
a showing iTreg in mLN of recipient mice (n  3). (B) Total number of
he mLN, small intestine lamina propria (SILP), Peyer’s patches (PP), and
Data from 8 independent experiments. *P  .05.nha
nim
fed
dat
in tvation of TGF- to maintain intestinal homeostasis.18–20
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1810 WORTHINGTON ET AL GASTROENTEROLOGY Vol. 141, No. 5A previous study has proposed that enhanced production
of the TGF- isoform TGF-2, latent associated binding
protein 3 (LTBP3), and tissue plasminogen activator (tPA)
by CD103 intestinal DCs may play roles in enhanced
Foxp3 iTreg induction.6 However, TGF-2 does not con-
tain the RGD integrin binding motif that would allow
engagement with integrin v8 and Ltbp-3 and tPA/
mice do not develop signs of colitis akin to mice lacking
v8 on DCs.9,21 Therefore although CD103 intestinal
DCs express an abundance of factors involved in TGF-
availability, our data clearly show that v8-mediated
GF- activation is the critical activator of TGF- respon-
ible for enhanced Treg induction in the intestine. Inter-
stingly, in lung cancer cells, it has been proposed that
ctivation of TGF- by integrin v8 involves presenta-
ion of the latent complex to the membrane metallopro-
ease MT1-MMP.22 However, we find no evidence for in-
reased expression of MT1-MMP in CD103 intestinal
Cs (Supplementary Figure 4). Hence, how CD103 DC-
expressed integrin v8 activates latent TGF- requires
urther investigation.
An important unanswered question is what is the key
ellular source of the TGF- that is activated by integrin
v8-expressing CD103 intestinal DCs? CD103 intes-
inal DCs show enhanced Foxp3 iTreg induction when
ultured with purified CD4 T cells, indicating that
TGF- production by either (or both) of these cell types is
ufficient to support iTreg induction. Interestingly, in
ice lacking TGF- expression specifically in T cells, total
ntestinal Foxp3 Treg numbers were unaltered, suggest-
ing that a TGF- source other than T cells may be im-
ortant in maintaining and/or inducing Foxp3 Tregs in
he gut.23 However, despite similar Foxp3 Treg numbers,
in the absence of T cell–derived TGF-, Foxp3 expression
levels in Tregs from the colonic lamina propria were
decreased, indicating that T cell–derived TGF- may play
some role in promoting Foxp3 Tregs in the gut.23 Alter-
atively, as shown in Figure 2, we found that CD103
intestinal DCs were able to activate more latent TGF-
than the CD103 subset when DCs were cultured only in
he presence of a TGF- reporter cell line, indicating that
C-expressed TGF- may be sufficient for the specialized
ability of these cells to activate TGF-.
In agreement with other studies,7,24,25 our data suggest
hat RA is not sufficient to cause enhanced Foxp3 iTreg
induction by CD103 intestinal DCs, and we now show
that RA can be dispensable for this function. Because
enhanced iTreg induction by intestinal CD103 DCs is
wholly dependent on their enhanced ability to activate
TGF-, an important question therefore is what are the
physiologic situations when RA can act to enhance iTreg
conversion in vivo? Studies have shown that RA acts
through the RAR receptor expressed on T cells to en-
ance TGF-–mediated Foxp3 induction26–29 but that
ice lacking RAR show normal Foxp3 Treg levels in
he lamina propria.27 Also, mice fed a vitamin A–deficient
diet from birth do not show reduced Foxp3 Treg num-
bers in the gut, at least in the small intestine.30 These datasuggest that the role of RA in regulating steady-state levels
of Foxp3 Tregs in the gut is minimal. This is in contrast
to the role of integrin v8-mediated TGF- activation,
ecause mice lacking this TGF-–activating integrin on
Cs not only show reduced levels of lamina propria
oxp3 Tregs, but also develop severe colitis under steady-
tate conditions.9
It is conceivable that RA acts to enhance Foxp3 iTreg
induction by CD103 intestinal DCs when TGF- levels
re up-regulated (eg, during the course of infection and
nflammation).31 An important function of RA is its abil-
ity to inhibit TGF-–driven induction of proinflamma-
ory IL-17–producing Th17 cells.25 Interestingly, our re-
cent data and that of others have highlighted an
important role for integrin v8-mediated TGF- activa-
ion by DCs in promoting Th17 cell induction in
ice.32,33 Hence, RA may act as an important regulator of
h17-mediated pathology in the gut, acting to dampen
ntegrin v8-mediated TGF- activation–driven Th17
cell induction by CD103 intestinal DCs during inflam-
atory responses.
It has been proposed that RA can enhance Foxp3 iTreg
induction indirectly by suppressing inflammatory cyto-
kine production by CD4 CD44hi memory T cells.27 These
ata would again support a role for RA in enhancing
Treg induction during active immune responses, via in-
ibition of inflammatory cytokine production by effector/
emory T cells.27 However, all iTreg induction experi-
ments described here were performed with naive CD4,
CD44/low, Foxp3 T cells, with enhanced iTregs still
induced by CD103 intestinal DCs in the absence/pres-
ence of RA. We have also performed similar assays, includ-
ing CD44hi T cells in culture, and again alterations in RA
function did not alter the enhanced iTreg induction by
CD103 intestinal DCs (Supplementary Figure 5 and data
ot shown). Our data therefore support a model where
A acts to enhance TGF-–mediated iTreg induction dur-
ing inflammatory events, either by directly enhancing
Foxp3 transcription,28 blocking inhibitory transcriptional
signals that prevent Foxp3 production,25,34 enhancing
TGF- signaling,35–37 or a combination of these.35 More
work is therefore required to determine the in vivo
situations where RA acts to enhance Treg induction in
the gut.
It is interesting to postulate which factors condition
CD103 intestinal DCs to express elevated integrin v8
evels and why CD103 intestinal DCs avoid similar con-
ditioning. CD103 binds to E-cadherin on intestinal epi-
thelial cells, which will expose CD103 DCs to an array of
ytokines that epithelial cells constitutively express during
omeostatic conditions. Such factors include thymic stro-
al lymphopoietin, interleukin-10, RA, and TGF- it-
elf,38 which alter DC function and could potentially
up-regulate integrin v8 expression. Similarly, activation
of TLR ligands by the microflora could enhance v8
xpression by DCs. It is probable that both CD103 and
D103 intestinal DC subsets respond to similar condi-tions in different ways as they arise from different hard-
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November 2011 TGF- ACTIVATION BY TOLEROGENIC GUT DENDRITIC CELLS 1811wired precursors.15 Interestingly, CD103 DCs from large
intestinal lamina propria showed a slight elevation in 8
xpression compared with CD103 DCs from small intes-
ine (Figure 5A), mLN, and spleen (data not shown), but
his enhanced integrin 8 expression did not result in
enhanced iTreg induction. These findings suggest a dif-
ferent functional role for 8 expression (and subsequent
TGF- activation) in these cells, which we are currently
nvestigating.
In conclusion, we have identified for the first time that
D103 intestinal DCs express increased levels of the
integrin v8, which is directly responsible for an in-
reased activation of TGF-, leading to an increased abil-
ity to induce Foxp3 iTregs in the steady state that is
ndependent of RA. Our data highlight a novel mecha-
ism in maintaining intestinal homeostasis and offer po-
ential specific treatments to modulate TGF- function,
via the manipulation of v8 integrin, to influence Treg
umbers during inflammatory diseases of the intestine.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2011.06.057.
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